Analyst Price Targets — TEVA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 6, 2026 9:48 am | — | Barclays | $40.00 | $35.86 | TheFly | Teva price target raised to $40 from $38 at Barclays |
| April 30, 2026 11:19 am | — | Piper Sandler | $42.00 | $35.38 | TheFly | Teva price target raised to $42 from $41 at Piper Sandler |
| April 30, 2026 10:55 am | — | UBS | $42.00 | $35.38 | TheFly | Teva price target raised to $42 from $36 at UBS |
| March 4, 2026 12:42 pm | David Amsellem | Piper Sandler | $41.00 | $32.64 | StreetInsider | Teva Pharma (TEVA) PT Raised to $41 at Piper Sandler; 'Much To Be Bullish About' |
| January 30, 2026 10:35 am | Glen Santangelo | Barclays | $38.00 | $33.07 | TheFly | Teva price target raised to $38 from $35 at Barclays |
| January 29, 2026 3:18 pm | — | Scotiabank | $40.00 | $32.90 | TheFly | Teva price target raised to $40 from $35 at Scotiabank |
| January 7, 2026 12:22 pm | — | Truist Financial | $36.00 | $32.11 | TheFly | Teva price target raised to $36 from $32 at Truist |
| January 6, 2026 12:37 pm | — | Jefferies | $40.00 | $31.00 | TheFly | Teva price target raised, named a top 2026 idea at Jefferies |
| December 22, 2025 11:44 am | — | Piper Sandler | $40.00 | $30.35 | TheFly | Teva price target raised to $40 from $30 at Piper Sandler |
| December 18, 2025 12:21 pm | — | Goldman Sachs | $35.00 | $30.06 | TheFly | Teva price target raised to $35 from $31 at Goldman Sachs |
Latest News for TEVA
One generates steady cash flow with a lower valuation; the other is growing at 45% but carries higher leverage.
Teva Pharmaceutical Industries NYSE: TEVA said its internally developed anti-IL-15 antibody produced encouraging 24-week efficacy results in a phase 1b proof-of-concept study for vitiligo, as the company highlighted the program as part of its broader shift toward a biopharma-focused growth strategy.
Novartis AG maintains a highly profitable portfolio of innovative medicines with significant net margins. Teva Pharmaceutical Industries is executing a turnaround focused on biosimilars and high-growth innovative assets.
Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG tod
TEL AVIV, Israel & ZUG, Switzerland--(BUSINESS WIRE)--Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics' proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval.…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.